722.57
price up icon0.44%   3.18
pre-market  Vorhandelsmarkt:  724.49   1.92   +0.27%
loading
Schlusskurs vom Vortag:
$719.39
Offen:
$719.23
24-Stunden-Volumen:
2.78M
Relative Volume:
0.69
Marktkapitalisierung:
$684.81B
Einnahmen:
$49.00B
Nettoeinkommen (Verlust:
$11.11B
KGV:
58.79
EPS:
12.29
Netto-Cashflow:
$-1.27B
1W Leistung:
+1.03%
1M Leistung:
-18.37%
6M Leistung:
-9.15%
1J Leistung:
-10.96%
1-Tages-Spanne:
Value
$716.96
$727.33
1-Wochen-Bereich:
Value
$709.00
$731.31
52-Wochen-Spanne:
Value
$677.09
$972.53

Lilly Eli Co Stock (LLY) Company Profile

Name
Firmenname
Lilly Eli Co
Name
Telefon
(317) 276-2000
Name
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Mitarbeiter
47,000
Name
Twitter
@LillyPad
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
LLY's Discussions on Twitter

Vergleichen Sie LLY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
LLY
Lilly Eli Co
722.57 642.06B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.58 367.19B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.62 322.44B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
112.58 222.20B 53.22B 12.86B 14.85B 6.39
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.46 302.90B 43.59B 15.04B 10.74B 3.3766

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-28 Herabstufung HSBC Securities Buy → Reduce
2025-04-22 Eingeleitet Cantor Fitzgerald Overweight
2024-12-10 Fortgesetzt BofA Securities Buy
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-10-17 Eingeleitet Bernstein Outperform
2024-09-13 Fortgesetzt Citigroup Buy
2024-08-12 Hochstufung Deutsche Bank Hold → Buy
2024-02-21 Herabstufung DZ Bank Buy → Hold
2024-02-16 Bestätigt Morgan Stanley Overweight
2023-12-21 Herabstufung Daiwa Securities Buy → Outperform
2023-11-09 Eingeleitet Deutsche Bank Hold
2023-10-20 Fortgesetzt UBS Buy
2023-08-09 Hochstufung Jefferies Hold → Buy
2023-07-26 Bestätigt Citigroup Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-24 Bestätigt BofA Securities Buy
2023-05-24 Bestätigt UBS Buy
2023-03-13 Hochstufung Wells Fargo Equal Weight → Overweight
2023-03-06 Eingeleitet Jefferies Hold
2023-02-15 Herabstufung Societe Generale Hold → Sell
2022-11-18 Eingeleitet Credit Suisse Outperform
2022-09-22 Hochstufung UBS Neutral → Buy
2022-05-23 Eingeleitet SVB Leerink Outperform
2022-04-06 Fortgesetzt Morgan Stanley Overweight
2022-03-10 Eingeleitet Daiwa Securities Outperform
2022-01-21 Hochstufung DZ Bank Hold → Buy
2022-01-03 Bestätigt Bernstein Mkt Perform
2021-12-17 Eingeleitet Goldman Neutral
2021-12-16 Bestätigt BMO Capital Markets Outperform
2021-12-16 Bestätigt BofA Securities Buy
2021-12-09 Fortgesetzt Wells Fargo Equal Weight
2021-11-19 Eingeleitet BMO Capital Markets Outperform
2021-10-11 Hochstufung Berenberg Hold → Buy
2021-09-29 Hochstufung Citigroup Neutral → Buy
2021-08-05 Hochstufung DZ Bank Hold → Buy
2021-07-27 Fortgesetzt Truist Buy
2021-06-24 Bestätigt Cantor Fitzgerald Overweight
2021-01-19 Hochstufung Mizuho Neutral → Buy
2020-12-10 Hochstufung Wolfe Research Peer Perform → Outperform
2020-11-10 Fortgesetzt Bernstein Mkt Perform
2020-09-29 Eingeleitet Berenberg Hold
2020-09-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-06-16 Hochstufung Guggenheim Neutral → Buy
2020-04-21 Herabstufung UBS Buy → Neutral
2020-04-09 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-06 Eingeleitet Mizuho Neutral
2019-12-18 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-10-17 Fortgesetzt BofA/Merrill Buy
2019-05-28 Eingeleitet Goldman Buy
2019-04-24 Hochstufung Edward Jones Hold → Buy
2019-04-11 Herabstufung Guggenheim Buy → Neutral
2019-03-12 Eingeleitet JP Morgan Overweight
2019-01-23 Eingeleitet UBS Buy
2018-11-26 Herabstufung Citigroup Buy → Neutral
2018-10-31 Hochstufung Credit Suisse Underperform → Neutral
2018-10-09 Eingeleitet Guggenheim Buy
2018-10-01 Bestätigt SunTrust Buy
2018-09-26 Fortgesetzt JP Morgan Overweight
Alle ansehen

Lilly Eli Co Aktie (LLY) Neueste Nachrichten

pulisher
May 29, 2025

Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On - TipRanks

May 29, 2025
pulisher
May 29, 2025

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions - Eli Lilly and Company

May 29, 2025
pulisher
May 29, 2025

Was Jim Cramer Right About Eli Lilly and Company (LLY)? - Insider Monkey

May 29, 2025
pulisher
May 29, 2025

UBS maintains Eli Lilly stock with $1,050 target - Investing.com

May 29, 2025
pulisher
May 29, 2025

Novo Is Losing Steam. Can It Oh, Oh, Oh, Obtain New Grounding? - Investor's Business Daily

May 29, 2025
pulisher
May 29, 2025

Eli Lilly : A Breakout Biotech Powerhouse With Room to Run - MarketBeat

May 29, 2025
pulisher
May 29, 2025

Eli Lilly (LLY) Gains Upper Hand in Weight-Loss Drug Market | LL - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

Ochre Bio appoints ex- Eli Lilly and AstraZeneca VP as Non-Executive Director - Health Tech World

May 29, 2025
pulisher
May 28, 2025

The weight loss war: Who is winning out between Novo-Nordisk and Eli Lilly? - Shares Magazine

May 28, 2025
pulisher
May 28, 2025

‘Start a Position’ in Eli Lilly Stock (LLY), Says Jim Cramer - TipRanks

May 28, 2025
pulisher
May 28, 2025

Is Eli Lilly And Company Stock Underperforming The Dow? - Barchart.com

May 28, 2025
pulisher
May 28, 2025

Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Lilly adds non-opioid painkiller to pipeline in $1B Siteone buyout - BioWorld MedTech

May 28, 2025
pulisher
May 28, 2025

BMO reiterates Eli Lilly stock with $900 target on SiteOne deal - Investing.com

May 28, 2025
pulisher
May 28, 2025

Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy? - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Lilly seeks to expand pain pipeline with $1B acquisition - dailyjournal.net

May 28, 2025
pulisher
May 28, 2025

Lilly to acquire biotech developing pain drugs - statnews.com

May 28, 2025
pulisher
May 28, 2025

Reports: Lilly eyes Houston for new $5.9B manufacturing facility - Indianapolis Business Journal

May 28, 2025
pulisher
May 28, 2025

Lilly to acquire SiteOne Therapeutics to expand pain pipeline - World Pharmaceutical Frontiers

May 28, 2025
pulisher
May 28, 2025

Eli Lilly to expand pain portfolio with SiteOne acquisition - Cleanroom Technology

May 28, 2025
pulisher
May 27, 2025

Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position” - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

Lilly snags Peninsula non-opioid pain drug company for up to $1 billionSan Francisco Business Times - The Business Journals

May 27, 2025
pulisher
May 27, 2025

Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med - MedCity News

May 27, 2025
pulisher
May 27, 2025

Lilly's Acquisition Of SiteOne Aims For Opioid AlternativesEli Lilly (NYSE:LLY) - Benzinga

May 27, 2025
pulisher
May 27, 2025

Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition - Insider Monkey

May 27, 2025
pulisher
May 27, 2025

Eli Lilly Inks $1B Deal For Non-Opioid Pain-Drug Maker - Law360

May 27, 2025
pulisher
May 27, 2025

Eli Lilly (LLY) Shows Strong Options Activity Amid Share Price Rise | LLY Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Eli Lilly to expand pain pipeline with $1bn SiteOne buyout - Pharmaceutical Technology

May 27, 2025
pulisher
May 27, 2025

Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug - Reuters

May 27, 2025
pulisher
May 27, 2025

Eli Lilly’s Strategic Acquisition of SiteOne Therapeutics Bolsters Pain Management Portfolio and Supports Buy Rating - TipRanks

May 27, 2025
pulisher
May 27, 2025

Eli Lilly (LLY) Expands into Pain Management Through Acquisition | LLY Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Eli Lilly (LLY) to Acquire SiteOne Therapeutics for $1 Billion - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Eli Lilly expands neuroscience pipeline with $1B SiteOne acquisition - Proactive financial news

May 27, 2025
pulisher
May 27, 2025

Seven top pharmas posted revenue declines in Q1. The common thread? All are US firms - Fierce Pharma

May 27, 2025
pulisher
May 27, 2025

Eli Lilly To Acquire SiteOne Therapeutics For Up To $1B To Advance Pain Management Pipeline: But Retail’s Unconvinced By Stocktwits - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Lilly to acquire SiteOne, enhancing non-opioid pain treatment options By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Lilly to acquire SiteOne, enhancing non-opioid pain treatment options - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics By Investing.com - Investing.com Nigeria

May 27, 2025
pulisher
May 27, 2025

Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics - Investing.com

May 27, 2025
pulisher
May 27, 2025

Eli Lilly (LLY) to Acquire SiteOne Therapeutics in $1 Billion De - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Eli Lilly’s SWOT analysis: stock poised for growth amid challenges - Investing.com

May 27, 2025
pulisher
May 27, 2025

Eli Lilly to acquire privately held SiteOne - Yahoo

May 27, 2025
pulisher
May 27, 2025

Eli Lilly & Co. (LLY) Acquires SiteOne Therapeutics - StreetInsider

May 27, 2025
pulisher
May 27, 2025

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company - Eli Lilly and Company

May 27, 2025
pulisher
May 27, 2025

Lilly Makes $1B Bet on Next-Generation Pain Treatment: Key Details of SiteOne Acquisition Revealed - Stock Titan

May 27, 2025
pulisher
May 27, 2025

Investment Case For Eli Lilly Still Weak, Despite Novo Nordisk's Struggle (NYSE:LLY) - Seeking Alpha

May 27, 2025
pulisher
May 27, 2025

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

May 27, 2025
pulisher
May 27, 2025

Lilly's blood drive breaks site record - reporter.net

May 27, 2025
pulisher
May 27, 2025

Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly - AOL.com

May 27, 2025
pulisher
May 26, 2025

Eli Lilly (LLY) Considers New $5.9 Billion Plant in Houston, Texas - TipRanks

May 26, 2025

Finanzdaten der Lilly Eli Co-Aktie (LLY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general JNJ
$153.58
price up icon 0.75%
$185.62
price up icon 1.38%
drug_manufacturers_general NVS
$112.58
price up icon 0.63%
drug_manufacturers_general NVO
$69.46
price up icon 1.25%
drug_manufacturers_general MRK
$76.40
price up icon 0.30%
Kapitalisierung:     |  Volumen (24h):